## **IN THE CLAIMS**:

Amend the claims as follows.

Claim 1-61. (Canceled)

62. (New) A compound of the formula:

$$Cy - Q^{1} - J - Q^{2} - C - N - OH$$
 (1)

wherein:

J is a linking functional group and is independently:

$$-C(=O)$$
- or  $-C(=O)$ - or  $-C(=O)$ -O-;

Cy is a cyclyl group and is independently:

 $C_{3\text{-}20} carbocyclyl,\ C_{3\text{-}20} heterocyclyl,\ or\ C_{5\text{-}20} aryl;$ 

and is optionally substituted;

Q<sup>1</sup> is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted;

Q<sup>2</sup> is an acid leader group, and is independently:

C<sub>1-8</sub>alkylene;

and is optionally substituted;

or:

Q<sup>2</sup> is an acid leader group, and is independently:

C<sub>5-20</sub>arylene;

C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene; or,

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

- 63. (New) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O-.
  - 64. (New) A compound according to claim 62, wherein J is -O-C(=O)-.
  - 65. (New) A compound according to claim 62, wherein J is -C(=O)-O-.
  - 66. (New) A compound according to claim 62, wherein J is -C(=O)-.

67. (New) A compound according to claim 62, wherein Q<sup>1</sup> is independently a group of the formula:



wherein:

the ring independently has from 4 to 7 ring atoms;

Z is independently -CH<sub>2</sub>-, -N(R<sup>N</sup>)- or -O-;


 $$R^N$$  , if present, is independently -H,  $C_{1\text{--}7}$  alkyl,  $C_{5\text{--}20}$  aryl- $C_{1\text{--}7}$  alkyl,  $C_{3\text{--}20}$  heterocyclyl, or  $C_{5\text{--}20}$  aryl; and

Q<sup>1</sup> is optionally further substituted.

68. (New) A compound according to claim 67, wherein Q<sup>1</sup> is independently a group of the formula:

wherein y is independently 1, 2, 3, or 4.

69. (New) A compound according to claim 68, wherein Q<sup>1</sup> is independently selected from:



70. (New) A compound according to claim 69, wherein Q<sup>1</sup> is independently:

71. (New) A compound according to claim 69, wherein Q<sup>1</sup> is independently:

72. (New) A compound according to claim 69, wherein Q<sup>1</sup> is independently:

- 73. (New) A compound according to claim 67, wherein R<sup>N</sup>, if present, is independently selected from: -H, -Me, -Et, -Ph, and -CH<sub>2</sub>-Ph.
- 74. (New) A compound according to claim 67, wherein R<sup>N</sup>, if present, is independently -H.
- 75. (New) A compound according to claim 62, wherein substituents on Q<sup>1</sup>, if present, are independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, -NH<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -CONH<sub>2</sub>, -CONMe<sub>2</sub>, -NHCOMe, and =O;

and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, -CF<sub>3</sub>.

- 76. (New) A compound according to claim 62, wherein Cy is independently C<sub>3-20</sub>carbocyclyl; and is optionally substituted.
- 77. (New) A compound according to claim 62, wherein Cy is independently C<sub>3-20</sub>heterocyclyl; and is optionally substituted.
- 78. (New) A compound according to claim 62, wherein Cy is independently C<sub>5-20</sub>aryl; and is optionally substituted.

- 79. (New) A compound according to claim 62, wherein Cy is independently  $C_{5-20}$  carboaryl or  $C_{5-20}$  heteroaryl; and is optionally substituted.
- 80. (New) A compound according to claim 62, wherein Cy is independently C<sub>5-20</sub> aryl derived from one of the following:

benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

- 81. (New) A compound according to claim 62, wherein Cy is independently C<sub>5-20</sub> aryl derived from benzene and is optionally substituted.
- 82. (New) A compound according to claim 62, wherein Cy is independently an optionally substituted phenyl group of the formula:

wherein n is independently an integer from 0 to 5, and each  $\mathbb{R}^A$  is independently a substituent.

- 83. (New) A compound according to claim 82, wherein n is 0.
- 84. (New) A compound according to claim 82, wherein n is 1, and the R<sup>A</sup> group is in the 4'-position.

- 85. (New) A compound according to claim 82, wherein n is 2, and one R<sup>A</sup> group is in the 4'-position, and the other R<sup>A</sup> group is in the 2'-position.
- 86. (New) A compound according to claim 82, wherein n is 2, and one R<sup>A</sup> group is in the 4'-position, and the other R<sup>A</sup> group is in the 3'-position.
- 87. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:
  - (1) ester;
  - (2) amido;
  - (3) acyl;
  - (4) halo;
  - (5) hydroxy;
  - (6) ether;
  - (7) C<sub>1-7</sub>alkyl; substituted C<sub>1-7</sub>alkyl;
  - (8)  $C_{5-20}$ aryl; substituted  $C_{5-20}$ aryl;
  - (9) sulfonyl;
  - (10) sulfonamido.
- 88. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:
  - (1) -C(=O)OR $^1$ , wherein R $^1$  is independently C $_{1-7}$ alkyl as defined in (7);

- (2) -C(=O)NR $^2$ R $^3$ , wherein each of R $^2$  and R $^3$  is independently -H or C $_{1-7}$ alkyl as defined in (7);
- (3) -C(=O)R $^4$ , wherein R $^4$  is independently C<sub>1-7</sub>alkyl as defined in (7) or C<sub>5-20</sub>aryl as defined in (8);
  - (4) -F, -Cl, -Br, -I;
  - (5) OH;
- (6) -OR $^5$ , wherein R $^5$  is independently  $C_{1-7}$ alkyl as defined in (7) or  $C_{5-20}$ aryl as defined in (8);
  - (7) C<sub>1-7</sub>alkyl; substituted C<sub>1-7</sub>alkyl;

halo-C<sub>1-7</sub>alkyl;

amino-C<sub>1-7</sub>alkyl;

carboxy-C<sub>1-7</sub>alkyl;

hydroxy-C<sub>1-7</sub>alkyl;

 $C_{1-7}$ alkoxy- $C_{1-7}$ alkyl;

 $C_{5-20}$ aryl- $C_{1-7}$ alkyl;

- (8) C<sub>5-20</sub>aryl; substituted C<sub>5-20</sub>aryl;
- (9)  $-SO_2R^7$ , wherein  $R^7$  is independently  $C_{1-7}$ alkyl as defined in (7) or  $C_{5-20}$  aryl as defined in (8);
- (10) -SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, wherein each of R<sup>8</sup> and R<sup>9</sup> is independently -H or  $C_{1-7}$ alkyl as defined in (7).
- 89. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),

-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe);

-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt;

(2)  $-(C=O)NH_2$ ,  $-(C=O)NMe_2$ ,  $-(C=O)NEt_2$ ,  $-(C=O)N(iPr)_2$ ,

## $-(C=O)N(CH_2CH_2OH)_2;$

- (3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;
- (4) -F, -Cl, -Br, -I;
- (5) -OH;
- (6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh;
- -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>;
- -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt;
- -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>;
- -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-

1;

- (7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe;
- -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>;
- -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt;
- -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>;
- -CH<sub>2</sub>-Ph;
- (8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;
- (9) -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph;
- (10) -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>.

90. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

-C(=O)OMe, -OMe, -C(=O)Me, -SO<sub>2</sub>Me, -SO<sub>2</sub>NMe<sub>2</sub>, -C(=O)NH<sub>2</sub>, -OCF<sub>3</sub>, and -CH<sub>2</sub>CH<sub>2</sub>OH.

91. (New) A compound according to claim 62, wherein the acid leader group, Q<sup>2</sup>, is independently:

C<sub>5-20</sub>arylene;

and is optionally substituted.

- 92. (New) A compound according to claim 62, wherein  $Q^2$  is independently  $C_{5-6}$  arylene; and is optionally substituted.
- 93. (New) A compound according to claim 62, wherein Q<sup>2</sup> is independently phenylene; and is optionally substituted.
- 94. (New) A compound according to claim 93, wherein the phenylene linkage is meta or para.
- 95. (New) A compound according to claim 93, wherein the phenylene linkage is meta.

- 96. (New) A compound according to claim 93, wherein the phenylene linkage is para.
- 97. (New) A compound according to claim 91, wherein Q<sup>2</sup> is independently unsubstituted.
- 98. (New) A compound according to claim 62, wherein the acid leader group, Q<sup>2</sup>, is independently:

C<sub>1-8</sub>alkylene;

and is optionally substituted.

- 99. (New) A compound according to claim 62, wherein Q<sup>2</sup> is independently:
  - (a) a saturated C<sub>1-7</sub>alkylene group; or:
  - (b) a partially unsaturated C<sub>2-7</sub>alkylene group; or:
  - (c) an aliphatic C<sub>1-7</sub>alkylene group; or:
  - (d) a linear C<sub>1-7</sub>alkylene group; or:
  - (e) a branched  $C_{2-7}$ alkylene group; or:
  - (f) a saturated aliphatic C<sub>1-7</sub>alkylene group; or:
  - (g) a saturated linear C<sub>1-7</sub>alkylene group; or:
  - (h) a saturated branched C2-7alkylene group; or:
  - (i) a partially unsaturated aliphatic  $C_{2\mbox{-}7}$  alkylene group; or:
  - (j) a partially unsaturated linear  $C_{2\mbox{-}7}$ alkylene group; or:
  - (k) a partially unsaturated branched  $C_{2-7}$ alkylene group;

and is optionally substituted.

100. (New) A compound according to claim 62, wherein Q<sup>2</sup> is independently selected from:

$$-(CH_2)_5$$
-;  $-(CH_2)_6$ -;  $-(CH_2)_7$ -; and  $-(CH_2)_8$ -.

101. (New) A compound according to claim 62, wherein Q<sup>2</sup> is independently:

C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene; or,

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

and is optionally substituted.

102. (New) A compound according to claim 62, wherein Q<sup>2</sup> is independently:

C<sub>5-6</sub>arylene-C<sub>1-7</sub>alkylene;

C<sub>1-7</sub>alkylene-C<sub>5-6</sub>arylene; or,

 $C_{1-7}$ alkylene- $C_{5-6}$ arylene- $C_{1-7}$ alkylene;

and is optionally substituted.

103. (New) A compound according to any claim 62, wherein  $\mathbf{Q}^2$  is independently:

phenylene-C<sub>1-7</sub>alkylene;

C<sub>1-7</sub>alkylene-phenylene; or,

C<sub>1-7</sub>alkylene-phenylene-C<sub>1-7</sub>alkylene;

and is optionally substituted.

104. (New) A compound according to claim 62, wherein Q<sup>2</sup> independently has a backbone of from 5 to 6 atoms.

105. (New) A compound according to claim 62, wherein each of the substituents on Q<sup>2</sup>, if present, is independently selected from:

halo, hydroxy, ether,  $C_{1-7}$ alkoxy,  $C_{5-20}$ aryl, acyl, amino, amido, acylamido, nitro, and oxo; and wherein, if a substituent is on an arylene group, it may additionally be selected from:  $C_{1-7}$ alkyl and substituted  $C_{1-7}$ alkyl.

106. (New) A compound according to claim 62, wherein each of the substituents on Q<sup>2</sup>, if present, is independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, -NH<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -CONH<sub>2</sub>, -CONMe<sub>2</sub>, -NHCOMe, -NO<sub>2</sub>, and =O; and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, -CF<sub>3</sub>.

107. (New) A compound of the formula:

$$Cy - Q^{1} - J - Q^{2} - C - N - OH$$
 (1)

wherein:

J is independently: -C(=O)-O-;

Q<sup>1</sup> is independently:

Q<sup>2</sup> is phenylene, and is optionally substituted;

Cy is phenyl, and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

108. (New) A compound selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof:


2	N OH	PX118479
3	O N OH N OH COOMe	PX118480
4	O CI	PX119101
5	OEt OEt	PX118925

6	COO(Me) <sub>3</sub>	PX118926
7	O O O O O O O O O O O O O O O O O O O	PX118959
8	OH NH OH	PX118966
9	OH NH OH	PX119058

10	O N OH	PX119059
11	O N OH	PX119061
12	O F S	PX119062
13	O N OH	PX119064

14	P OH	PX119065
15	O N OH	PX119084
16	O O O O O O O O O O O O O O O O O O O	PX119100
17	OMe OMe	PX119063

18	O Ph	PX119085
19	C(Me) <sub>3</sub>	PX119086
20	O OH	PX119102 <sub>.</sub>
21	OH NOH	PX119103



109. (New) A composition comprising a compound according to claim 62 and a pharmaceutically acceptable carrier.

110. (New) A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to claim 62.

111. (New) A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to claim 62.

112. (New) A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to claim 62.

113. (New) A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to claim 62.

114. (New) A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to claim 62.